Drug Delivery Technologies And Regulatory Compliance Under Indian Pharmaceutical Laws
International Journal of Drug Delivery Technology · 21.04.2026 · 16 (15s)
DOI: 10.25258/ijddt.16.15s.3 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 21.04.2026. Verfasst von Dr. Prodipta Barman und 5 weiteren Autor:innen.
Abstract (Originalsprache)
India's pharmaceutical industry, ranked third globally by volume and thirteenth by value, occupies a pivotal position in the global supply of generic medicines, vaccines, and advanced drug formulations. The rapid emergence of novel drug delivery technologies — encompassing nanoparticle-based systems, liposomal carriers, transdermal patches, implantable devices, targeted biological therapies, and controlled-release oral formulations — has fundamentally transformed the therapeutic landscape while simultaneously generating profound regulatory challenges. The Central Drugs Standard Control Organisation (CDSCO), operating under the Drugs and Cosmetics Act of 1940 and its 1945 Rules, constitutes the primary regulatory authority governing the approval, manufacture, and post-market surveillance of pharmaceutical products in India. However, the existing legislative and regulatory architecture was conceived primarily for conventional dosage forms and is increasingly strained by the complexity and novelty of advanced drug delivery systems (DDS). This paper provides a comprehensive examination of the intersection between contemporary drug delivery technologies and the regulatory compliance framework under Indian pharmaceutical law. It critically analyses the adequacy of current legislative provisions — including Schedule M (Good Manufacturing Practices), the New Drugs and Clinical Trials Rules 2019, and the Biological Drugs Regulation — in addressing the safety, efficacy, and quality requirements of novel DDS. The paper further evaluates the institutional capacity of CDSCO, the evolving role of the Indian Pharmacopoeia Commission, and the alignment of Indian regulatory standards with international benchmarks set by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The paper concludes by identifying critical regulatory gaps and proposing systemic reforms necessary to enable India to sustain its position as a global pharmaceutical leader while ensuring robust patient safety.
Zitieren
APA
Barman, D. P., Rani, D. A., Grover, C., Goyal, D. G. P., Bhartiya, D. S., & Chandra, P. D. P. (2026). Drug Delivery Technologies And Regulatory Compliance Under Indian Pharmaceutical Laws. International Journal of Drug Delivery Technology, 16(15s). https://doi.org/10.25258/ijddt.16.15s.3
Vancouver
Barman DP, Rani DA, Grover C, Goyal DGP, Bhartiya DS, Chandra PDP. Drug Delivery Technologies And Regulatory Compliance Under Indian Pharmaceutical Laws. International Journal of Drug Delivery Technology. 2026;16(15s). doi:10.25258/ijddt.16.15s.3
BibTeX
@article{Barman2026,
author = {Barman, Dr. Prodipta and Rani, Dr. Arti and Grover, Charu and Goyal, Dr. Govind Prasad and Bhartiya, Dr. Shalini and Chandra, Prof. (Dr.) Prem},
title = {Drug Delivery Technologies And Regulatory Compliance Under Indian Pharmaceutical Laws},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {15s},
doi = {10.25258/ijddt.16.15s.3}
}
EUVIMED